Compare Abeona Therapeutics Inc (ABEO) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Norwegian Cruise Line Holdings Ltd — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Norwegian Cruise Line Holdings Ltd trades at $18.47 (market cap $8.65B). The key difference: Norwegian Cruise Line Holdings Ltd is far larger — about 23.2× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Norwegian Cruise Line Holdings Ltd nearer its low. Which is the better fit depends on your goals.
| ABEO | NCLH | |
|---|---|---|
Market Cap | $373.32M | $8.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $26.94 |
52-Week Low | $4.17 | $14.79 |
Enterprise Value | $228.22M | $23.61B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
NCLH trades at $18.83, down 4.8% on the day, reflecting near-term pressure amid a bearish technical signal. The company has demonstrated consistent earnings beats, with Q1 2026 EPS of $0.23 exceeding the $0.15 estimate. Fundamentals show a P/E of 15.53 and a net income margin of 5.66%, while recent news highlights new executive appointments and future cruise itineraries. The stock is trading below the consensus analyst price target of $22.00.
The outlook is mixed; strong earnings performance and a favorable valuation offer upside potential, but high debt levels and a bearish technical trend present significant risks. The stock's performance is closely tied to travel demand and macroeconomic factors affecting the cruise industry.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
